Get the Stockscreener App
30.26
0.67%
0.20
After Hours:
29.30
-0.96
-3.17%
Kiniksa Pharmaceuticals International Plc stock is traded at $30.26, with a volume of 617.58K.
It is up +0.67% in the last 24 hours and up +9.36% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$30.06
Open:
$30.06
24h Volume:
617.58K
Relative Volume:
0.79
Market Cap:
$1.28B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-216.14
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+12.49%
1M Performance:
+9.36%
6M Performance:
+54.39%
1Y Performance:
+13.76%
1-Day Range:
$29.90
$30.84
1-Week Range:
$26.27
$31.92
52-Week Range:
$17.82
$31.92
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
30.26 | 2.19B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Victory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High Following Better-Than-Expected Earnings - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates - MSN
Kiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration rises - MSN
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... - Yahoo.co
Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67 - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High After Strong Earnings - Defense World
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals Reports Q2 2025 Financial Results with 52% Growth in ARCALYST Revenue and Updates on Clinical Trials - Quiver Quantitative
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Crushes Earnings: ARCALYST Sales Jump 52%, Company Raises 2025 Revenue Target to $640M - Stock Titan
Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Buy” by Analysts - Defense World
Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call. - AInvest
Cwm LLC Has $491,000 Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Cerity Partners LLC Purchases 12,110 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings: Key Financial Results Coming July 29How to Join - Stock Titan
Cerity Partners LLC Boosts Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Ltd. Stock Analysis and ForecastExceptional gains - Autocar Professional
BlackRock, Inc. Significantly Reduces Holdings in Kiniksa Pharmaceuticals International PLC - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Teacher Retirement System of Texas Decreases Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 18,900 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Kiniksa Pharmaceuticals COO Eben Tessari Buys, Sells Shares on July 14 - AInvest
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLC - Defense World
Wealth Enhancement Advisory Services LLC Invests $301,000 in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals Surges 7.24% on July 9 Amid Analyst Predictions - AInvest
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - Defense World
KNSA: Analyst Maintains Overweight Rating, Raises Price Target | - GuruFocus
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
Allspring Global Investments Holdings LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Allspring Global Investments Holdings LLC Raises Holdings in Broadstone Net Lease, Inc. (NYSE:BNL) - Defense World
Wealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth - AOL.com
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Peregrine Capital Management LLC Purchases 65,147 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Asset Management One Co. Ltd. Makes New $41,000 Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
AMI Asset Management Corp Has $1.73 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Genentech ends ulcerative colitis study for drug from $700 million dealSan Francisco Business Times - The Business Journals
GAMMA Investing LLC Purchases 26,826 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari Sells 17,300 Shares - MarketBeat
Rhumbline Advisers Acquires 3,745 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa pharma COO Tessari sells $489k in shares By Investing.com - Investing.com South Africa
Kiniksa pharma COO Tessari sells $489k in shares - Investing.com
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha
Lewis & Ellis acquires Huggins Actuarial Services - Yahoo
UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):